ArticleViruses2023
In-Depth Analysis of the Re-Emergence of Respiratory Syncytial Virus at a Tertiary Care Hospital in Germany in the Summer of 2021 after the Alleviation of Non-Pharmaceutical Interventions Due to the SARS-CoV-2 Pandemic.
Article in Viruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- Burden of respiratory syncytial virus (RSV) infection in Germany: a systematic review.BMC infectious diseases · 2024Pooled it
- A decade of endemic human coronaviruses: epidemiological patterns and clinical significance in an adult cohort at a tertiary care hospital in Germany.BMC infectious diseases · 2026Article
- Update on the Incidence of Paediatric Multiple Sclerosis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease, Aquaporin-4 Antibody-Positive Neuromyelitis Optica Spectrum Disorder, and Other Acquired Demyelinating Syndromes in the Netherlands, 2017-2025, Including the COVID-19 Pandemic.European journal of neurology · 2026Article
- Clinical and human burden of respiratory syncytial virus in older adults: a narrative review with emphasis on Italian data.Aging clinical and experimental research · 2026Review
- New Tools Against Old Enemies: Respiratory Syncytial Virus (RSV) in Older Adults. A Narrative Review.Farmaceuticos comunitarios · 2026Article
- Article
- Genetic diversity and molecular characterization of HRSV-A on the coast of Peru, 2009-2020.Frontiers in microbiology · 2026Article
- Long-term impact of the SARS-CoV-2 pandemic on respiratory viruses in Germany.BMC public health · 2025Article
- Burden of disease and seasonal data of children hospitalized due to RSV and Influenza infection before, during and after the COVID-19 pandemic.European journal of pediatrics · 2025Article
- Costs and Complications of Respiratory Syncytial Virus and Acute Respiratory Infections in the Adult Population: Analysis of a German Claims Database.PharmacoEconomics - open · 2025Article
- Genotypic Characterization of Human Respiratory Syncytial Viruses Detected in Mexico Between 2021 and 2024.Viruses · 2025Article
- Changes in Respiratory Viruses' Activity in Children During the COVID-19 Pandemic: A Systematic Review.Journal of clinical medicine · 2025Review
- Influence of COVID-19 public health restrictions on community-acquired pneumonia pathogens in children in Henan, China: a multicenter retrospective study.BMC infectious diseases · 2024Article
- Coxsackievirus A6 U.K. Genetic and Clinical Epidemiology Pre- and Post-SARS-CoV-2 Emergence.Pathogens (Basel, Switzerland) · 2024Article
- Epidemiological and Clinical Insights into the Enterovirus D68 Upsurge in Europe 2021-2022 and Emergence of Novel B3-Derived Lineages, ENPEN Multicentre Study.The Journal of infectious diseases · 2024Article
- Severe respiratory syncytial virus disease.Journal of intensive medicine · 2024Review
- Article
- Comparison of the Burden and Temporal Pattern of Hospitalisations Associated With Respiratory Syncytial Virus (RSV) Before and After COVID-19 in New Zealand.Influenza and other respiratory viruses · 2024Article
- Article
- Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Following the extensive non-pharmaceutical interventions (NPIs) and behavioral changes in the wake of the SARS-CoV-2 pandemic, an interseasonal rise in respiratory syncytial virus (RSV) cases was observed in Germany in 2021. The aim of this study was to characterize the local molecular epidemiology of RSV infections in comparison to the three pre-pandemic seasons. Additionally, clinical data were retrieved from patient charts to determine the clinical significance of RSV infections. RSV detections peaked in calendar week 40 of 2021, 18 weeks earlier than the usual peak observed in the three pre-pandemic seasons. Sequence analysis revealed a close phylogenetic relatedness regardless of the season of origin. A significantly higher amount of pediatric cases (88.9% of all cases,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.